Research Topics
Genomes and GenesSpecies | B EscudierSummaryAffiliation: Institut Gustave Roussy Country: France Publications
| Collaborators
|
Detail Information
Publications
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanomaBernard Escudier
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Clin Cancer Res 13:1801-9. 2007..To determine the safety, maximum tolerated dose, pharmacokinetics, and efficacy, and to evaluate biomarkers, of the multikinase inhibitor sorafenib plus IFN alpha-2a in advanced renal cell carcinoma (RCC) or melanoma...
Optimal management of metastatic renal cell carcinoma: current statusBernard Escudier
Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France
Drugs 73:427-38. 2013..Finally, optimal therapy for non-clear cell RCC remains to be delineated, although sunitinib, everolimus and other VEGFR-TKI or mTOR inhibitors have all demonstrated modest benefit...- How to select amongst available options for the treatment of advanced RCC?B Escudier
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France
Ann Oncol 23:x309-12. 2012..The different options are described in this manuscript... - Emerging immunotherapies for renal cell carcinomaB Escudier
Department of Medical Oncology, Institut Gustave Roussy, Villejuif Paris Sud, France
Ann Oncol 23:viii35-40. 2012..Novel therapies used in combination or sequentially have the potential to improve outcomes in mRCC, and results from ongoing/planned trials will shape future therapy... - [Treatment of metastatic kidney cancer in elderly subjects]B Escudier
Unité d Immunothérapie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif, France
Prog Urol 19:S129-32. 2009..Given the data available today, no dose adaptation in relation to age is recommended in metastatic renal cancer... - Advanced renal cell carcinoma: current and emerging management strategiesBernard Escudier
Institut Gustave Roussy, Villejuif, France
Drugs 67:1257-64. 2007..However, many questions still remain regarding the efficacy of combination treatments and on the best way to achieve complete remission, which is probably the best hope of curing MRCC... - Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialBernard Escudier
Institut Gustave Roussy, Villejuif, France
J Clin Oncol 27:3312-8. 2009.... - Sunitinib for the management of advanced renal cell carcinomaBernard Escudier
Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
Expert Rev Anticancer Ther 10:305-17. 2010..This paper presents an overview of data supporting the use of sunitinib for mRCC, and considers the optimal management of sunitinib in clinical practice... - [Metastatic renal cell carcinoma and its treatments]B Escudier
Unité d Immunothérapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
Ann Urol (Paris) 40:S82-5. 2006.... - Sequential therapy in renal cell carcinomaBernard Escudier
Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
Cancer 115:2321-6. 2009..Expecting a survival of 40 months does appear possible based on currently available data, although this assumption will have to be proven in the future... - Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinomaBernard Escudier
Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
J Clin Oncol 27:1280-9. 2009.... - Sorafenib for the management of advanced renal cell carcinomaBernard Escudier
Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
Expert Rev Anticancer Ther 11:825-36. 2011..This article reviews the expansive clinical evidence supporting the use of sorafenib in RCC, including analyses across a variety of subpopulations, and examines the impact of sorafenib on clinical practice and its future role in RCC... - Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinomaBernard Escudier
Institut Gustave Roussy, Villejuif, France
Drugs 71:1179-91. 2011..Ongoing trials evaluating novel anti-VEGF therapies could establish whether the increased potency and selectivity of these agents results in improved efficacy and tolerability in RCC patients, further improving their prognosis... - Sorafenib in advanced clear-cell renal-cell carcinomaBernard Escudier
Department of Medicine, Institut Gustave Roussy, Villejuif, France
N Engl J Med 356:125-34. 2007..We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma... - Phase II trial of thalidomide in renal-cell carcinomaB Escudier
Institut Gustave Roussy, Villejuif, France
Ann Oncol 13:1029-35. 2002..Thalidomide has been reported to yield anti-tumor activity in cancer. We performed a phase II trial of this drug in patients with metastatic renal cell carcinoma to determine its efficacy... - Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialBernard Escudier
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Lancet 370:2103-11. 2007..Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted... - Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'ImmunothérapeB Escudier
Institut Gustave Roussy, Villejuif, France
J Clin Oncol 17:2039-43. 1999..To determine whether either of these cytokines might be efficient after failure of the other, we analyzed a series of patients treated with either IL-2 or IFNalpha2a as second-line treatment after failure of the other cytokine... - Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survivalBernard Escudier
Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
J Clin Oncol 28:2144-50. 2010..A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC). Here, we report overall survival (OS) data... - [Targeted therapies: sequential and combined treatments]M Gross-Goupil
Institut Gustave Roussy, 114, rue Edouard Vaillant, 94805, Villejuif, France
Bull Cancer 97:65-71. 2010.... - Sequential sorafenib and sunitinib for renal cell carcinomaM P Sablin
Institut Gustave Roussy, Villejuif, France
J Urol 182:29-34; discussion 34. 2009..In many patients sequential administration of the 2 drugs occurs because of the lack of sustained efficacy of the first agent. We determined the efficacy and safety of sequential administration... - [Renal cell carcinoma management and therapies in 2010]B Albouy
Institut Gustave Roussy, Departement de Medecine, 39, rue Camille Desmoulins, 94805 Villejuif, France
Bull Cancer 97:17-28. 2010..Prospective trials will be assessed the value of nephrectomy in patients treated by antiangiogenic therapies. Large randomized trial are ongoing to evaluate these new therapies in adjuvant setting... - Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancerS Rajpar
Department of Medicine, Institut Gustave Roussy, University of Paris XI, Villejuif, France
Ann Oncol 21:1864-9. 2010..The aim of this study was to assess the prognostic value of uNTx for overall survival (OS) and the incidence of SRE in patients with bone metastases from CRPC receiving zoledronic acid... - [New drugs in metastatic castration-resistant prostate cancer]L Albiges
Institut Gustave Roussy, Departement de Medecine, 39 rue Camille Desmoulins, 94800 Villejuif, France
Bull Cancer 97:149-59. 2010..A recent analogue of thalidomide, probably more efficient, lenalidomide is also in development... - Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'ImmunothérapieA Ravaud
Department of Medicine, Institut Bergonie, Bordeaux, France
J Clin Oncol 16:2728-32. 1998..A phase II trial was designed to determine the efficacy and the tolerance of interleukin-2 (IL-2), interferon alfa-2a (IFNalpha), and fluorouracil (5-FU) in patients with metastatic renal cell carcinoma... - Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC NetworkG G Malouf
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 21:1834-8. 2010..We analyzed the benefit of targeted therapy [vascular endothelial growth factor receptor (VEGFR)-targeted agents and/or mammalian target of rapamycin (mTOR) inhibitors] in these patients... - Novel and bone-targeted agents for CRPCK Fizazi
Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France
Ann Oncol 23:x264-7. 2012..benefit? Can we personalise treatment based on the biology of the individual's disease? How will we develop new active compounds in the context where a half dozen approved agents may confound their potential overall survival effect?.. - Incidence of brain metastases in renal cell carcinoma treated with sorafenibC Massard
Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
Ann Oncol 21:1027-31. 2010..i.d.), versus placebo in the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET)... - Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine featuresY Loriot
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 20:703-8. 2009..The purpose of this study was to prospectively assess the anticancer activity and tolerance of the carboplatin-etoposide combination in this setting while evaluating neuroendocrine (NE) features... - The postchemotherapy PSA surge syndromeR Thuret
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 19:1308-11. 2008..The objective of this work was to study early serum PSA changes in patients under chemotherapy and to correlate these changes with subsequent response assessment... - How to select targeted therapy in renal cell cancerB Escudier
Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
Ann Oncol 21:vii59-62. 2010..In addition, in front of every patient, the physician will need to raise important questions such as whether the patient should be treated, should receive surgery and also what is his prognosis. The different options are described here... - Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinibB Beuselinck
Department of Medical Oncology, Hopital Europeen Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
Ann Oncol 22:794-800. 2011..The aim of our study was to determine whether the presence of bone metastases affects outcomes in patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) receiving sunitinib... - Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitorsT Bessede
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 22:2320-4. 2011..The objective of the study was to investigate possible sexual disorders in a male population with advanced RCC treated with a molecular targeted therapy (MTT)... - To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasoundMichele Lamuraglia
Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
Eur J Cancer 42:2472-9. 2006..CONCLUSION: DCE-US is a new noninvasive imaging technique which might be an effective tool for evaluating antiangiogenic drugs in renal cancer... - Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?C Massard
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 21:1585-8. 2010..The management of these patients was modified at Institut Gustave Roussy in 1997 to try to avoid this complication... - Sorafenib [corrected] in kidney cancerB Escudier
Institut Gustave Roussy, Villejuif, France
Ann Oncol 18:ix90-3. 2007 - Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitorJulien Autier
Dermatology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Arch Dermatol 144:886-92. 2008..To provide an accurate description and to evaluate the incidence and severity of cutaneous reactions induced by sorafenib tosylate, a new oral multikinase inhibitor... - Exosomes for cancer immunotherapyF Andre
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 15:iv141-4. 2004 - Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinomaS Antoun
Department of Supportive Care, Institut Gustave Roussy, Villejuif, France
Ann Oncol 21:1594-8. 2010..i.d. Weight, height and skeletal muscle cross-sectional area at the third lumbar vertebra were measured by computed tomography (CT). Toxicity was assessed... 
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitorsF Farace
Translational Research Laboratory, Institut de Cancerologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
Br J Cancer 104:1144-50. 2011....- The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancerYohann Loriot
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Eur J Cancer 46:1770-2. 2010..The interval from the last cycle of first-line docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel... - Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancerSylvie Negrier
Universite de Lyon, Centre Leon Berard, Medical Oncology Department, Institut National de la Sante et de la Recherche Medicale U 590 and Biostatistics Unit, Centre Leon Berard, Lyon Cedex 08, France
Clin Cancer Res 14:5907-12. 2008..A French immunotherapy intergroup multicenter trial assessed the potential benefit of i.v. over s.c. administration of IL-2 in this combination... - [Eruptive nevi associated with sorafenib treatment]M Bennani-Lahlou
Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, France
Ann Dermatol Venereol 135:672-4. 2008..Cutaneous side effects are frequent with sorafenib, but no naevus modification has been reported until now... - Signaling inhibitors in metastatic renal cell carcinomaBernard Escudier
Institut Gustave Roussy, Villejuif, France
Cancer J 14:325-9. 2008..However, many questions still remain on the efficacy of combination treatments and on the best way to get complete remission, which is probably the best way to lead to cure of metastatic renal cell cancer in the future... - Bevacizumab: direct anti-VEGF therapy in renal cell carcinomaBernard Escudier
Immunotherapy Unit, Institut Gustave Roussy, Villejuif Cedex, France
Expert Rev Anticancer Ther 8:1545-57. 2008..Trials over the next 5 years will guide clinical practice, but bevacizumab plus IFN is currently a standard first-line option for mRCC... - Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled studySami Antoun
Department of Supportive Care, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
J Clin Oncol 28:1054-60. 2010..Muscle loss is specifically exacerbated by sorafenib, consistent with the evidence for a role of kinases in regulating muscle mass. Muscle loss is a sorafenib adverse effect that may relate to asthenia, fatigue, and physical disability... - Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinomaBernard Escudier
Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
J Clin Oncol 27:4068-75. 2009..Herein, we report results of an open-label, multicenter phase II mRCC study of sunitinib administered on a continuous once-daily dosing regimen... - Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancerKarim Fizazi
Department of Medicine, Institut Gustave Roussy, Villejuif, France
J Clin Oncol 27:2429-35. 2009..To assess docetaxel combined with samarium-153-ethylene diamine tetramethylene phosphonic acid (EDTMP), a radiopharmaceutical with a high affinity for bone, in patients with castration-resistant prostate cancer (CRPC)... - Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941Bernard Escudier
Institut Gustave Roussy, Villejuif, France
J Urol 178:1901-5. 2007..We analyzed prognostic factors, described survival and generated a prognostic model in patients with metastatic renal cell carcinoma in whom immunotherapy failed and who were potentially eligible for novel agents... - Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) studyStephane Oudard
Medical Oncology Department, Georges Pompidou European Hospital, Rene Descartes University, Paris, France
J Urol 177:1698-702. 2007.... - Dermatologic symptoms associated with the multikinase inhibitor sorafenibCaroline Robert
Department of Medicine, Dermatology Unit, Institut Gustave Roussy, Villejuif, France
J Am Acad Dermatol 60:299-305. 2009..The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms... - Cutaneous side-effects of kinase inhibitors and blocking antibodiesCaroline Robert
Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
Lancet Oncol 6:491-500. 2005..Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response... - Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinomaEmilie Viey
Institut National de la Santé et de la Recherche Médicale U487IFR 54, Institut Gustave Roussy, 94805 Villejuif, France
Expert Rev Anticancer Ther 5:973-86. 2005.... - [Interest of color Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma]Nathalie Lassau
Unité d échographie, Departement d Imagerie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
Bull Cancer 91:629-35. 2004..Twenty eight had tumor targets which could be evaluated by DUS. Before treatment, the volume was studied in 59 tumors and the vascularity in 54 tumors. During treatment, comparative DUS examinations were performed every 6 weeks... - A phase II study of irinotecan in patients with advanced renal cell carcinomaKarim Fizazi
Département de Médecine Institut Gustave Roussy, Villejuif, France
Cancer 98:61-5. 2003..Therefore, the authors tested the antitumor activity of irinotecan in patients with RCC... - Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201)Patrick Saulnier
Centre de Référence IGR Aventis Gencell, Institut Gustave Roussy, 39, rue Camille Desmoulins, F 94805 Villejuif, France
J Virol Methods 114:55-64. 2003.... - Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patientsF Griscelli
Department of Biology, Institut Gustave Roussy, Villejuif, France
Gene Ther 10:386-95. 2003..In addition, only on the day of the injection was Ad.RSVbetagal also detected in E1-positive PBL, indicating that virus replication in blood was very unlikely... - High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activityK Fizazi
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 18:518-21. 2007..Telomerase activation, one of the major immortalization events, is found in most cases of prostate cancer. We attempted to develop a method using telomerase activity to isolate CTCs in patients with prostate cancer... - Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier
Institut Gustave Roussy, Villejuif, , Lyon, France
J Urol 168:959-61. 2002..9 months. A single patient died of toxicity. CONCLUSIONS: The results do not support the standard use of doxorubicin/ifosfamide chemotherapy in patients with metastatic sarcomatoid renal cell carcinoma... - Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinomaJudith Michels
Institut Gustave Roussy, Departement de Medecine, Villejuif, France
Invest New Drugs 28:690-3. 2010..Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome... - CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signalingAsma Gati
, , 94805 Villejuif, France
Cancer Res 63:7475-82. 2003..These studies provide evidence that tumor cells selectively favor the local persistence of nonfunctional KIR+ CTLs by promoting their survival... - Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinomaEmilie Viey
, , Institut Gustave Roussy, Villejuif, France
J Immunol 174:1338-47. 2005..These results outline that Vgamma9Vdelta2-TCR effectors may represent a promising approach for the treatment of metastatic renal cell carcinoma... - Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patientsAsma Gati
INSERM, Institut Gustave Roussy, Villejuif, France
Int J Cancer 109:393-401. 2004..Although LFA-1/ICAM-1 interaction potentiates RCC cell lysis, HLA-I/NKR interaction clearly decreased RCC cell susceptibility to NK cells. In addition, proliferation of NK cells from MRCC patients in response to cytokines was altered... - Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interactionNadia Guerra
Institut National de la Santé et de la Recherche Médicale INSERM U487 and Unité des Thérapies innovantes, Institut Gustave Roussy, and Institut Andre Lwoff CNRS, Hopital Paul Brousse, Villejuif, France
Blood 100:2874-81. 2002..Accordingly, the expression of CD158 by TILs may favor tumor cell escape to the immune response... - [Exosomes and anti-tumour immunotherapy]Nathalie Chaput
, , Institut Gustave-Roussy, 39 rue Camille-Desmoulins, 94805 Villejuif, France
Bull Cancer 90:695-8. 2003..Here, we will focus on the biological features pertaining to dendritic cell- and tumor cell derived-exosomes and will discuss their potential clinical implementation... - Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15RalphaSophie Viaud
Institut National de la Sante et de la Recherche Medicale, Unité 805, Villejuif, France
PLoS ONE 4:e4942. 2009..Altogether, these data provide a mechanistic explanation on how Dex may stimulate non MHC restricted-anti-tumor effectors and induce tumor regression in vivo... - Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levelsChristoph Rochlitz
Departement Innere Medizin, Abteilung für Onkologie, Kantonsspital, Petersgraben 4, CH 4031 Basel, Switzerland
Cancer Gene Ther 9:289-95. 2002..The objectives of this study were to evaluate the tolerance and incidence of tumor regression in patients with metastatic melanoma, following repeated administration of Vero-IL-2 cells... - Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'ImmunotherapieSylvie Negrier
Cytokines and Cancer Research Unit, INSERM U 590 and Medical Oncology Department, Cedex 08, France
J Clin Oncol 22:2371-8. 2004..Our objective was to analyze the prognostic value of circulating vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), and interleukin-6 (IL-6)... - [Metastatic kidney cancer: new therapeutic approaches]Sylvie Negrier
Departement d Oncologie Medicale, Centre Leon Berard, 28, rue Laennec, 69373 Lyon, France
Prog Urol 12:703-8. 2002..Finally, various molecules with promising antiangiogenic properties are currently under development in renal cancer... - Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?Caroline Robert
Ann Intern Med 143:313-4. 2005 - CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent mannerFrancois Ghiringhelli
ERM 0208, Institut National de la Sante et de la Recherche Medicale INSERM, University of Paris XI, France
J Exp Med 202:1075-85. 2005..Human NK cell-mediated tumor recognition could also be restored by depletion of T reg cells from tumor-infiltrating lymphocytes. These findings support a role for T reg cells in blunting the NK cell arm of the innate immune system... - Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialRobert J Motzer
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lancet 372:449-56. 2008..We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy... - Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinomaToni K Choueiri
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 26:127-31. 2008..The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated... - Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trialSylvie Negrier
Universite de Lyon, Department of Medical Oncology and Cytokines and Cancer Research Unit, Leon Berard Center, INSERM U590, Lyon, France
Cancer 110:2468-77. 2007..The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments... - Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patientsEmilie Viey
Institut National de la Santé et de la Recherche Médicale U753, from Institut Fédératif de Recherche 54 Villejuif, France
J Immunother 31:313-23. 2008.... - Anti-VEGF therapy for renal cell carcinomaBernard Escudier
Immunotherapy and Innovative Therapy Unit, Institut Gustave-Roussy, Paris 94805, France
Clin Adv Hematol Oncol 5:530-1. 2007 - [Clinical results of Nexavar for the treatment of kidney cancer]Bernard Escudier
Prog Urol 17:150-3. 2007 - Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancerRonald Bukowski
CCF Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
Am J Clin Oncol 30:220-7. 2007..The aim of the current study was to determine the impact of treatment with sorafenib versus placebo on renal cancer symptoms and quality of life (QOL)... - Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinomaMartin E Gore
Department of Medicine, The Royal Marsden Hospital NHS Trust, London, England
Oncology (Williston Park) 20:19-24. 2006..Issues surrounding study endpoints and biologic efficacy markers for molecular targeted agents in RCC are discussed in this article, with a focus on results of the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGETs)... - [New entities in pathological classification and new therapeutic options in renal cell carcinoma]Jacques Olivier Bay
Departement d Oncologie Medicale, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont Ferrand
Bull Cancer 93:91-100. 2006..Finally, we will present targeted therapy (antiangiogenic drugs and tyrosine kinase inhibitors) with the mechanisms of action, efficacy and appropriate use in the treatment of metastatic renal cell carcinoma... - Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trialTim Eisen
The Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK
J Natl Cancer Inst 100:1454-63. 2008..It is not known how older patients respond to targeted therapy... - [Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group]Sylvie Negrier
Departement d Oncologie Medicale, Centre Leon Berard, 28, rue Laennec, 69373 Lyon
Prog Urol 12:213-8. 2002..c. cytokine regimens are therefore fairly disappointing. These results were taken into account in the ongoing evaluation programme (Percy programme) based on patient selection as a function of prognostic factors... - Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cellsNicolas van Baren
Ludwig Institute for Cancer Research, 74 avenue Hippocrate, UCL7459, B 1200 Brussels, Belgium E mail
J Clin Oncol 23:9008-21. 2005.... - Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCNEmma R Woodward
Cancer Research UK Renal Molecular Oncology Group and Department of Medical and Molecular Genetics, University of Birmingham and West Midlands Regional Genetics Service, Birmingham Women s Hospital, United Kingdom
Clin Cancer Res 14:5925-30. 2008.... - [Kidney tumors]Arnaud Mejean
Prog Urol 17:1101-44. 2007 - Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanomaWim H J Kruit
Erasmus Medical Center-Daniel den Hoed Cancer Center, Department of Internal Oncology, Rotterdam, The Netherlands
Int J Cancer 117:596-604. 2005.... - Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'ImmunothérapieSylvie Negrier
Department of Biostatistics, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08 France
World J Urol 23:161-5. 2005..Patients who combine at least three of these factors have over 80% probability of rapid progression despite treatment. We think that these results must be taken into account for cytokine treatment decision... - An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trialChristopher Wood
M D Anderson Cancer Center, Houston, TX, USA
Lancet 372:145-54. 2008.... - Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosisSebastian Wittnebel
Institut National de la Santé et de la Recherche Médicale U753, France
Cancer Res 67:5594-9. 2007..Masking of MbIL-15 with soluble IL-15Ralpha molecules restored NK cell apoptosis. These findings suggest that IL-15 produced by renal tumor cells is involved in the maintenance of active NK cells at the tumor site...